Phoenix Biotech Acquisition Corp.
PBAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $3 | $3 | $7 |
| G&A Expenses | $2 | $2 | $2 | $7 |
| SG&A Expenses | $2 | $2 | $2 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $4 | $5 | $5 | $14 |
| Operating Income | -$4 | -$5 | -$5 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$7 | -$25 | -$1 | $6 |
| Pre-Tax Income | -$12 | -$30 | -$5 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$30 | -$5 | -$9 |
| % Margin | – | – | – | – |
| EPS | -9.1 | -61.71 | -0.11 | -0.18 |
| % Growth | 85.3% | -56,000% | 38.9% | – |
| EPS Diluted | -9.1 | -61.71 | -0.11 | -0.18 |
| Weighted Avg Shares Out | 1 | 0 | 50 | 50 |
| Weighted Avg Shares Out Dil | 1 | 0 | 50 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$4 | -$5 | -$5 | -$8 |
| % Margin | – | – | – | – |